Form 4: Spyre Therapeutics Director Acquires Stock Options

Director Michael Thomas Henderson acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. on May 14, 2024.

Summary

• On May 14, 2024, Michael Thomas Henderson, a director of Spyre Therapeutics, Inc. (SYRE), acquired stock options.
• The options grant the right to purchase 11,323 shares of the company's common stock at an exercise price of $39.29 per share.
• The options vest in 12 equal monthly installments starting May 14, 2024, contingent upon Henderson's continued service with the company.
• The options expire on May 14, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard stock option grant to a director, which is generally viewed as a positive sign of alignment between management and shareholders. It suggests confidence in the company's future, but it's a routine event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the director to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule of 12 months is fairly standard.
• Comparing the size of the grant to similar companies would require further analysis of Spyre Therapeutics' compensation policies and market capitalization.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates